Literature DB >> 19050380

Post-step modifications for research on HIV vaccines.

Lawrence Corey, M Juliana McElrath, James G Kublin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19050380      PMCID： PMC2720076          DOI： 10.1097/QAD.0b013e32830e6d6d

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  27 in total

1.  Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.

Authors:  Alexandre Harari; Florence Vallelian; Pascal R Meylan; Giuseppe Pantaleo
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

Review 2.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

Authors:  Dan H Barouch; Gary J Nabel
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

3.  Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

Authors:  Ulrike Wille-Reece; Chang-You Wu; Barbara J Flynn; Ross M Kedl; Robert A Seder
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

4.  Towards prediction of degenerate CTL epitope recognition.

Authors:  Fusheng Li; Denise M McKenney; Uma Malhotra; Claire Crimi; Jessica Nolin; Lawrence Corey; Juliana M McElrath; Mark J Newman; Steven G Self
Journal:  Hum Vaccin       Date:  2007-10-26

5.  Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Authors:  Danilo R Casimiro; Fubao Wang; William A Schleif; Xiaoping Liang; Zhi-Qiang Zhang; Timothy W Tobery; Mary-Ellen Davies; Adrian B McDermott; David H O'Connor; Arthur Fridman; Ansu Bagchi; Lynda G Tussey; Andrew J Bett; Adam C Finnefrock; Tong-ming Fu; Aimin Tang; Keith A Wilson; Minchun Chen; Helen C Perry; Gwendolyn J Heidecker; Daniel C Freed; Anthony Carella; Kara S Punt; Kara J Sykes; Lingyi Huang; Virginia I Ausensi; Margaret Bachinsky; Usha Sadasivan-Nair; David I Watkins; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.

Authors:  Caroline L Smith; Fareed Mirza; Valerie Pasquetto; David C Tscharke; Michael J Palmowski; P Rod Dunbar; Alessandro Sette; Adrian L Harris; Vincenzo Cerundolo
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

8.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

9.  Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

Authors:  Gerrit Koopman; Daniella Mortier; Sam Hofman; Henk Niphuis; Zahra Fagrouch; Steve Norley; Gerd Sutter; Peter Liljeström; Jonathan L Heeney
Journal:  J Gen Virol       Date:  2004-10       Impact factor: 3.891

Review 10.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

Authors:  John W Shiver; Emilio A Emini
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739
View more
  34 in total

Review 1.  Cofactors that may influence vaccine responses.

Authors:  Guy de Bruyn
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise.

Authors: 
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

3.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

Review 4.  Weighing the gold in the gold standard: challenges in HIV prevention research.

Authors:  Nancy S Padian; Sandra I McCoy; Jennifer E Balkus; Judith N Wasserheit
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

Review 5.  New approaches to design HIV-1 T-cell vaccines.

Authors:  Hélène Perrin; Glenda Canderan; Rafick-Pierre Sékaly; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 6.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

7.  The STEP study provides a hint that vaccine induction of the right CD8+ T cell responses can facilitate immune control of HIV.

Authors:  Marcus Altfeld; Philip J Goulder
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

8.  Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection.

Authors:  Vitaly V Ganusov; Nilu Goonetilleke; Michael K P Liu; Guido Ferrari; George M Shaw; Andrew J McMichael; Persephone Borrow; Bette T Korber; Alan S Perelson
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

9.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.